2018 American Transplant Congress
Reducing No-Show Rate and Filling Cancelled Appointments: Multi-Faceted Interventions Markedly Reduced Time to Kidney Transplant Evaluation
Piedmont Transplant Institute, Piedmont Atlanta Hospital, Atlanta, GA.
Introduction: Time from referral to appointment for kidney transplant evaluation is an important metric. Demands of dialysis schedules and transportation logistics typically lead to high…2018 American Transplant Congress
Procurement Travel Safety: Current Practices, Accident Frequency, Perceptions of Safety and Means to Reduce Risk
Emory Transplant Center, Emory University, Atlanta, GA.
Transplant procurement teams travel extensively. Though considered hazardous, little data on the necessity and risks of this travel exist. We conducted a survey of ASTS…2017 American Transplant Congress
Five Year Outcomes with Alemtuzumab Induction Therapy in Elderly Renal Transplant Recipients.
Pharmacy, Northwestern Memorial Hospital, Chicago, IL
Background:The elderly population (≥ 65 years) comprise one fourth of patients on the waiting list for renal transplantation. Alemtuzumab use has increased over the past…2017 American Transplant Congress
Donor Derived Transmission Events in 2015-2016: Analysis of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
1DTAC, Richmond; 2United Network for Organ Sharing, Richmond
The OPTN DTAC, a multidisciplinary committee, evaluates potential donor derived transmission events (PDDTE), including mostly infections (I) & malignancies (M), to assess for likelihood of…2017 American Transplant Congress
A Phase-Two, Randomised, Placebo-Controlled Trial: Belimumab in Renal Transplantation Targets Naïve, Activated Memory and Antibody Producing B Cells Whilst Sparing Regulatory B Cells.
This phase 2, double-blind, randomised controlled study (BEL114424) explores the safety and potential efficacy of addition of belimumab to standard of care in renal transplantation…2017 American Transplant Congress
Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Solid Organ Transplant Recipients: A Phase 2 Study.
Study NCT01611974 assessed safety, tolerability, and antiviral activity of maribavir (MBV) for treatment of resistant or refractory (R/R) CMV infections among transplant recipients. Those aged…2017 American Transplant Congress
Subclinical Rejections in Kidney Transplant Recipients Treated with Direct Acting Antiviral Agents for Hepatitis C Treatment within 1 Year of Transplant.
Direct acting antiviral agents (DAA) have revolutionized the management of Hepatitis C virus (HCV) positive kidney transplant recipients (KTR). The optimal timing of DAA therapy…2017 American Transplant Congress
Improving Value by Standardizing the Use of IVIG Amongst Pediatric Solid Organ Transplant (SOT) Patients.
Background: Given the high cost of pharmaceuticals (i.e. IVIG), we sought to determine if unnecessary variation in drug use may be an opportunity to improve…2017 American Transplant Congress
Safety of Liver Donation from Living Donors with Sickle Cell Trait.
Background:Living donor liver transplant (LDLT) is an important source of organs particularly with the cadaveric organ shortage. It is the main source of liver transplant…2017 American Transplant Congress
Risk of Major Bleeding in Solid Organ Transplant Recipients Taking Calcineurin Inhibitors Concomitantly with Direct Oral Anticoagulants Compared to Warfarin.
Pharmacy, CHI St. Luke's Health-Baylor St. Luke's Medical Center, Houston, TX
Purpose: Direct oral anticoagulants (DOAC) and calcineurin inhibitors (CNI) are both substrates of CYP 3A metabolism; therefore, the purpose of this study is to assess…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 19
- Next Page »